Search research articles
Contact Us
Filters
Showing results (91-100 of 139) with videos related to
Page
of 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2015
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer
E Deutsch, C Le Péchoux, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2013
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
B Besse, R S Heist, V A Papadmitrakopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J-M Michot, L Albiges, N Chaput, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 28, 2011
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
T C Gauler, B Besse, A Mauguen, et al.
ESMO Open
|
March 5, 2023
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
C M Rudin, A Cervantes, A Dowlati, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
February 11, 2020
[Role of immunotherapy in locally advanced non-small cell lung cancer]
A Levy, J Doyen, A Botticella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
E Felip, A T Shaw, A Bearz, et al.
Revue Des Maladies Respiratoires
|
June 8, 2011
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]
G Meyer, B Besse, S Friard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
S Novello, B Besse, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors
F Barlési, C Balleyguier, B Besse, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 139) with videos related to
Sort By:
Page
of 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2015
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer
E Deutsch, C Le Péchoux, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2013
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
B Besse, R S Heist, V A Papadmitrakopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J-M Michot, L Albiges, N Chaput, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 28, 2011
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
T C Gauler, B Besse, A Mauguen, et al.
ESMO Open
|
March 5, 2023
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
C M Rudin, A Cervantes, A Dowlati, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
February 11, 2020
[Role of immunotherapy in locally advanced non-small cell lung cancer]
A Levy, J Doyen, A Botticella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
E Felip, A T Shaw, A Bearz, et al.
Revue Des Maladies Respiratoires
|
June 8, 2011
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]
G Meyer, B Besse, S Friard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
S Novello, B Besse, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors
F Barlési, C Balleyguier, B Besse, et al.
Page
of 14